# US 2022/0011309 A1 · Method for the rapid identification of covid-19 infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0011309 A1
- Document ID: US20220011309A1
- Status: Published application
- Kind: A1
- Application number: 17/370,514
- Filed: 2021-07-08
- Published: 2022-01-13
- Earliest claimed: 2020-07-08
- Assignees: Arizona Board of Regents on behalf of Arizona State University; Marv Enterprises, LLC
- Applicants: Arizona Board of Regents On Behalf of Arizona State University; Marv Enterprises LLC
- Inventors: Qiang Chen; Mitchell S. Felder
- Web page: https://patentgrep.com/patent/US20220011309A1

## CPC

- G01N 33/56983: {Viruses}
- G01N 33/54366: {Apparatus specially adapted for solid-phase testing}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/6854: {Immunoglobulins}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

An embodiment provides a method for identifying Covid-19 in a body fluid of a patient, including: removing the body fluid from a patient; applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody; identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source; and returning the body fluid to the patient. Other aspects are described and claimed.

## Claims

### Claim 1

A method for identifying Covid-19 in a body fluid of a patient, comprising:
removing the body fluid from a patient;
applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody; and
identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source.

### Claim 2 (depends on 1)

The method of claim 1, wherein the Covid-19 targeted antigen is selected from the group consisting of: Covid-19 spike glycoprotein, Covid-19 M-Protein, Covid-19 Hemoglutinesterase dimer, Covid-19 Envelope, Covid-19 E-Protein, Covid-19 N-Protein, nsp (non-structural protein) 12 RNA-dependent RNA polymerase (nsp 12), nsp (non-structural protein) 7, nsp 8, nsp 14, nsp 12-nsp 7-nsp 8 complex, nsp?-nsp8 complex, nsp10-nsp14 complex, and nsp10-nsp16 complex.

### Claim 3 (depends on 1)

The method of claim 1, wherein the light functional antibody comprises a luminescent antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the light functional antibody comprises a fluorescent antibody.

### Claim 5 (depends on 1)

The method of claim 1, wherein the identifying the antibody-TA complex comprises an intense energy beam to properly illuminate the antibody-TA complex.

### Claim 6 (depends on 1)

The method of claim 1, wherein the identifying the antibody-TA complex comprises a control unit to determined Covid-19 positivity in the body fluid.

### Claim 7 (depends on 1)

The method of claim 1, further comprising capturing the antibody-TA complex with an antibody microarray.

### Claim 8 (depends on 7)

The method of claim 7, wherein the microarray comprises a plurality of the antibody on a solid surface.

### Claim 9 (depends on 8)

The method of claim 8, wherein the solid surface comprises a transparent material.

### Claim 10 (depends on 1)

The method of claim 1, wherein the identifying comprises at least one sensor to identify the light functional antibody.

### Claim 11

A device for identifying Covid-19 in a body fluid of a patient, comprising:
a transparent first stage including an inlet for the body fluid and at least one exterior wall defining a treatment chamber;
a transparent second stage, fluidly connected to the first stage, comprising a removal module and an outlet for the body fluid, wherein the treatment chamber comprises a delivery tube for introducing an antibody into the treatment chamber, wherein the delivery tube comprises a hollow tube including at least one interior wall defining a plurality of holes through which the antibody can be added to the treatment chamber, wherein the treatment is delivered through the hollow tube in counter-current mode with reference to the body fluid; and
at least one sensor to identify the light functional antibody;
the device being configured to:
remove the body fluid from a patient;
apply a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody; and
identify the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source.

### Claim 12 (depends on 11)

The device of claim 11, wherein the Covid-19 targeted antigen is selected from the group consisting of: Covid-19 spike glycoprotein, Covid-19 M-Protein, Covid-19 Hemoglutinesterase dimer, Covid-19 Envelope, Covid-19 E-Protein, Covid-19 N-Protein, nsp (non-structural protein) 12 RNA-dependent RNA polymerase (nsp 12), nsp (non-structural protein) 7, nsp 8, nsp 14, nsp 12-nsp 7-nsp 8 complex, nsp7-nsp8 complex, nsp10-nsp14 complex, and nsp10-nsp16 complex.

### Claim 13 (depends on 11)

The device of claim 11, wherein the light functional antibody comprises a luminescent antibody.

### Claim 14 (depends on 11)

The device of claim 11, wherein the light functional antibody comprises a fluorescent antibody.

### Claim 15 (depends on 11)

The device of claim 11, wherein the identifying the antibody-TA complex comprises an intense energy beam to properly illuminate the antibody-TA complex.

### Claim 16 (depends on 11)

The device of claim 11, wherein the identifying the antibody-TA complex comprises a control unit to determined Covid-19 positivity in the body fluid.

### Claim 17 (depends on 11)

The device of claim 11, further comprising capturing the antibody-TA complex with an antibody microarray.

### Claim 18 (depends on 17)

The device of claim 17, wherein the microarray comprises a plurality of the antibody on a solid surface.

### Claim 19 (depends on 18)

The device of claim 18, wherein the solid surface comprises a transparent material.

### Claim 20

A method for identifying Covid-19 in a body fluid of a patient, comprising:
removing the body fluid from a patient;
applying a treatment to the body fluid, wherein the treatment comprises an antibody that joins with a Covid-19 targeted antigen (TA) in the body fluid to form an antibody-TA complex, wherein the antibody comprises a light functional antibody;
identifying the antibody-TA complex, using a spectroscopic technique, from the body fluid using a light source;
capturing, using an antibody microarray, the antibody-TA complex, wherein the microarray comprises a plurality of the antibody on a transparent solid surface; and
returning the body fluid to the patient.
